ArticleJournal of translational medicine2025
IL-1β-induced STAT3 activation drives IL-17-producing CD8
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The multifaceted role of NF-κB signaling in psoriasis: from inflammatory amplification to epidermal remodeling.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe accumulation of IL-17–producing CD8+ tissue-resident memory T (IL-17+ CD8+ TRM) cells contributes to chronic and recurrent psoriasis. Suppressor of cytokine signaling 3 (SOCS3) plays a critical role in limiting pSTAT3 and pNF-κB activity to restrain excessive IL-17–mediated inflammation. This study investigated how IL-1–induced activation of pSTAT3 and pNF-κB leads to SOCS3 downregulation in CD8+ TRM cells, facilitating the expansion of IL-17+ subsets in psoriasis. It also evaluated the therapeutic potential of restoring SOCS3 through targeted STAT3 inhibition and STAT5 activation.
methodsUsing both in vitro assays and an IL-1 receptor antagonist knockout mouse model of imiquimod-induced psoriasis, we examined hyperactive IL-1 signaling in CD8+ TRM cells isolated from ex vivo psoriatic samples. The STAT3 inhibitor STA-21 was used to assess its effect on SOCS3 expression and IL-17+ CD8+ TRM cells frequency.
resultsHyperactivation of IL-1 signaling in chronic psoriasis established a pathogenic NF-κB-STAT3 feedback loop in CD8+ TRM cells, where elevated pSTAT3 and pNF-κB activity suppressed SOCS3 expression, promoting the expansion of IL-17+ CD8+ TRM cells and exacerbating disease severity. Therapeutic modulation via STA-21 restored SOCS3 levels, reduced IL-17+ CD8+ TRM numbers, and attenuated the pathogenic feedback loop. Dual regulation of STAT3 inhibition and STAT5 activation emerged as a promising approach to attenuate psoriatic inflammation.
conclusionOur findings demonstrate that the IL-1/pNF-κB/pSTAT3 axis in CD8+ TRM cells as a major contributor of psoriasis pathogenesis. Restoring SOCS3 expression through combined STAT3 inhibition and STAT5 activation represents a potential immunomodulatory approach that may contribute to treatment strategies for severe or recurrent psoriasis. However, further studies, including direct comparisons with current biological combination therapies, are needed to fully evaluate its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.